Oncology · Colorectal CancerTrial Updateclinicalmid-term

Yale University Launches Pragmatic Trial for Colorectal Cancer Screening Adherence

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/19/2026, 6:30:46 PM

Assessment confidence: 66% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The Yale University trial aims to enhance adherence to colorectal cancer screening, which is crucial for early detection and treatment. The outcomes may reveal effective strategies that can be leveraged by pharma and biotech companies to improve their screening programs and align with evolving clinical guidelines. Regulatory context from FDA (Verified Clinical Benefit | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 12 ranked evidence items (7 high-relevance).

Strategic Assessment

Pharma and biotech the outcomes of this trial to identify successful strategies that could be integrated into their own screening programs. The strongest clinical anchor is MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In colorectal cancer, 5 regulatory and 1 competitive items passed relevance filtering for colorectal cancer diagnostics.

Competitive Pressure

The most relevant competitive pressure comes from SEPTIN9 methylation in ctDNA predicts MRD in colorectal cancer patients post-surgery (Humanexa Signals) — sub-indication match (colorectal cancer). This trial may provide insights into effective strategies for increasing screening rates, potentially impacting market dynamics for colorectal cancer diagnostics and interventions.

Regulatory Outlook

Regulatory risk is concentrated around Verified Clinical Benefit | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. The trial's findings may influence future screening guidelines, potentially affecting regulatory requirements for colorectal cancer diagnostics and interventions.

Key Risks

Elevated medium regulatory exposure for colorectal cancer diagnostics could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful strategies identified in this trial could lead to increased market share for companies that adapt their products or services accordingly, enhancing their competitive positioning in the colorectal cancer space.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Pharma and biotech the outcomes of this trial to identify successful strategies that could be integrated into their own screening programs.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results and final outcomes of the trial, which could influence future screening guidelines and product development.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Verified Clinical Benefit | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Other | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of Late-stage Cancer Diagnosis in an Asymptomatic Population?
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Rumination-Tailored Guided Internet-Based CBT-I for University Students
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

SEPTIN9 methylation in ctDNA predicts MRD in colorectal cancer patients post-surgery
Humanexa Signalshigh relevance
Sub-indication match (colorectal cancer)
KEYTRUDA Shows Significant PFS Improvement in dMMR Endometrial Cancer in Phase 3 Trial
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Discovery of a novel and potent KRAS(G12V)-targeting peptide with antiproliferative activity against colorectal cancer cells.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Early prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Cervical cancer and screening: Knowledge, attitudes, and adherence among university students in Italy.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

colorectal cancer diagnostics
biotech companies
pharma companies

Commercial impact

medium

Successful strategies identified in this trial could lead to increased market share for companies that adapt their products or services accordingly, enhancing their competitive positioning in the colorectal cancer space.

Regulatory impact

medium

The trial's findings may influence future screening guidelines, potentially affecting regulatory requirements for colorectal cancer diagnostics and interventions.

What to watch

Key milestones include interim results and final outcomes of the trial, which could influence future screening guidelines and product development.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.